research use only
Cat.No.S2866
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Carbonic Anhydrase Inhibitors | Indisulam (E7070) Benzenesulfonamide Tioxolone 2-Aminobenzenesulfonamide |
|
In vitro |
DMSO
: 62 mg/mL
(200.43 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 309.32 | Formula | C13H12FN3O3S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 178606-66-1 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | MST-104, NSC 213841, SLC-0111, WBI-5111 | Smiles | C1=CC(=CC=C1NC(=O)NC2=CC=C(C=C2)S(=O)(=O)N)F | ||
| Targets/IC50/Ki |
CAXII
(Cell-free assay) 4.5 nM(Ki)
CAIX
(Cell-free assay) 45.1 nM(Ki)
|
|---|---|
| In vitro |
U-104 (50 μM) blocks the mesenchymal phenotype in the cancer stem cells population in hypoxia condition of 4T1 cells. This compound (<50 μM) significantly reduces migration in a dose-dependent manner in metastatic MDA-MB-231 LM2-4Luc+ cells , with cells growing as compact colonies similar to parental MDA-MB-231 cells. This chemical possesses aromatic groups at the second nitrogen ureido group.
|
| In vivo |
U-104 (38 mg/kg) inhibits primary tumor growth in the mice implanted orthotopically with MDA-MB-231 LM2-4Luc+ cells. This compound (19 mg/kg) inhibits metastases formation in the 4T1 experimental metastasis mice model. This chemical (38 mg/kg) significantly delay primary tumor growth and reduces cancer stem cell population in NOD/SCID mice orthotopically implanted with MDA-MB-231 LM2-4Luc+ cells. It (5 mg/mL, oral gavage) shows a significant delay in tumor growth in Balb/c mice orthotopically implanted with 4T1 cells.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03450018 | Recruiting | Metastatic Pancreatic Ductal Adenocarcinoma |
British Columbia Cancer Agency|Canadian Cancer Society (CCS)|SignalChem Lifesciences Corporation |
January 10 2019 | Phase 1|Phase 2 |
| NCT02215850 | Completed | Solid Tumours |
Welichem Biotech Inc.|Ozmosis Research Inc. |
October 2014 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.